A disintegrin and metalloprotease (ADAM) 33 protein in patients with pulmonary sarcoidosis

Respirology

Volumn 17, Issue 2, 2012, Pages 342-349

  Shaffiq, Asif ^a   Haitchi, Hans Michael ^a   Pang, Yun Yung ^a   Alangari, Abdullah A ^a,c   Jones, Mark G ^a   Marshall, Ben G ^b   Howarth, Peter H ^a,b   Davies, Donna E ^a,b   O'Reilly, Katherine M A ^b  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

^c KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

a disintegrin and metalloproteinase protein; biological marker; inflammation; remodelling; sarcoidosis

Indexed keywords

A DISINTEGRIN AND METALLOPROTEASE 33; ADAM PROTEIN; IMMUNOGLOBULIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; FORCED VITAL CAPACITY; HUMAN; LUNG FUNCTION; LUNG LAVAGE; MALE; PRIORITY JOURNAL; SARCOIDOSIS;

ADAM PROTEINS; ADULT; AGED; BIOLOGICAL MARKERS; BLOTTING, WESTERN; BRONCHOALVEOLAR LAVAGE FLUID; BRONCHOSCOPY; DIAGNOSIS, DIFFERENTIAL; FEMALE; FLUORESCENCE RESONANCE ENERGY TRANSFER; FOLLOW-UP STUDIES; HUMANS; MALE; MICROSCOPY; MIDDLE AGED; SARCOIDOSIS, PULMONARY; SEVERITY OF ILLNESS INDEX;

EID: 84856264706     PISSN: 13237799     EISSN: 14401843     Source Type: Journal    
DOI: 10.1111/j.1440-1843.2011.02098.x     Document Type: Article

References (30)

1. Van Eerdewegh P, Little RD, Dupuis J, et al,. Association of the ADAM-33 gene with asthma and bronchial hyper-responsiveness. Nature 2002; 418: 426-30. (Pubitemid 34826843)
2. Gosman MM, Boezen HM, van Diemen CC, et al,. A Disintegrin And Metalloproteinase 33 and chronic obstructive pulmonary disease pathophysiology. Thorax 2007; 62: 242-7. (Pubitemid 46579805)
3. Jongepier H, Boezen HM, Dijkstra A, et al,. Polymorphisms of the ADAM33 gene are associated with accelerated lung function decline in asthma. Clin. Exp. Allergy 2004; 34: 757-60. (Pubitemid 38736791)
4. van Diemen CC, Postma DS, Vonk JM, et al,. A Disintegrin A Metalloprotease 33 polymorphisms and lung function decline in the general population. Am. J. Respir. Crit. Care Med. 2005; 172: 329-33. (Pubitemid 41026143)
5. Simpson A, Maniatis N, Jury F, et al,. Polymorphisms in A Disintegrin and Metalloprotease 33 (ADAM33) predict impaired early-life lung function. Am. J. Respir. Crit. Care Med. 2005; 172: 55-60. (Pubitemid 40923314)
6. Powell RM, Wicks J, Holloway JW, et al,. The splicing and fate of ADAM33 transcripts in primary human airways fibroblasts. Am. J. Respir. Cell Mol. Biol. 2004; 31: 13-21. (Pubitemid 38888034)
7. Blobel CP,. Remarkable roles of proteolysis on and beyond the cell surface. Curr. Opin. Cell Biol. 2000; 12: 606-12.
8. Puxeddu I, Pang YY, Harvey A, et al,. The soluble form of a disintegrin and metalloprotease 33 promotes angiogenesis: implications for airway remodeling in asthma. J. Allergy Clin. Immunol. 2008; 121: 1400-6.
9. Lee JY, Park SW, Chang HK, et al,. A disintegrin and metalloproteinase 33 protein in patients with asthma: relevance to airflow limitation. Am. J. Respir. Crit. Care Med. 2006; 173: 729-35.
10. Nunes H, Soler P, Valeyre D,. Pulmonary sarcoidosis. Allergy 2005; 60: 565-82. (Pubitemid 40562463)
11. Henry MT, McMahon K, Mackarel AJ, et al,. Matrix metalloproteinases and tissue inhibitor of metalloproteinase-1 in sarcoidosis and IPF. Eur. Respir. J. 2002; 20: 1220-7. (Pubitemid 35331881)
12. Elkington PT, Friedland JS,. Matrix metalloproteinases in destructive pulmonary pathology. Thorax 2006; 61: 259-66.
13. Antoniou KM, Tzouvelekis A, Alexandrakis MG, et al,. Different angiogenic activity in pulmonary sarcoidosis and idiopathic pulmonary fibrosis. Chest 2006; 130: 982-8. (Pubitemid 44583725)
14. National Heart, Lung, and Blood Institute workshop summary. Investigative use of bronchoscopy, lavage and bronchial biopsies in asthma and other airways diseases. Eur. Respir. J. 1992; 5: 115-21.
15. Statement on sarcoidosis. Joint statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999. Am. J. Respir. Crit. Care Med. 1999; 160: 736-55.
16. Lesueur F, Oudot T, Heath S, et al,. ADAM33, a new candidate for psoriasis susceptibility. PLoS ONE 2007; 2: e906.
17. Kawaguchi N, Xu X, Tajima R, et al,. ADAM 12 protease induces adipogenesis in transgenic mice. Am. J. Pathol. 2002; 160: 1895-903. (Pubitemid 34525669)
18. Hotoda N, Koike H, Sasagawa N, et al,. A secreted form of human ADAM9 has an alpha-secretase activity for APP. Biochem. Biophys. Res. Commun. 2002; 293: 800-5. (Pubitemid 34687259)
19. Haitchi H-M, Bassett D, Bucchieri F, et al,. Induction of ADAM33 during embryonic lung development and the influence of interleukin-13 or maternal allergy. J. Allergy Clin. Immunol. 2009; 124: 590-7.
20. Zou J, Zhang R, Zhu F, et al,. ADAM33 enzyme properties and substrate specificity. Biochemistry 2005; 44: 4247-56. (Pubitemid 40403965)
21. McDonald DM,. Angiogenesis and remodeling of airway vasculature in chronic inflammation. Am. J. Respir. Crit. Care Med. 2001; 164: S39-S45.
22. Roy R, Zhang B, Moses MA,. Making the cut: protease-mediated regulation of angiogenesis. Exp. Cell Res. 2006; 312: 608-22. (Pubitemid 43290337)
23. Takemura T, Hiraga Y, Oomichi M, et al,. Ultrastructural features of alveolitis in sarcoidosis. Am. J. Respir. Crit. Care Med. 1995; 152: 360-6.
24. Weber J, Meyer KC, Banda P, et al,. Studies of bronchoalveolar lavage cells and fluids in pulmonary sarcoidosis. II. Enhanced capacity of bronchoalveolar lavage fluids from patients with pulmonary sarcoidosis to induce cell movement in vitro. Am. Rev. Respir. Dis. 1989; 140: 1450-4. (Pubitemid 19276240)
25. Koyama S, Sato E, Haniuda M, et al,. Decreased level of vascular endothelial growth factor in bronchoalveolar lavage fluid of normal smokers and patients with pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2002; 166: 382-5. (Pubitemid 34864431)
26. Hoshino M, Takahashi M, Aoike N,. Expression of vascular endothelial growth factor, basic fibroblast growth factor, and angiogenin immunoreactivity in asthmatic airways and its relationship to angiogenesis. J. Allergy Clin. Immunol. 2001; 107: 295-301. (Pubitemid 32173907)
27. Wolff H, Teppo AM, Mutanen P, et al,. Studies of cytokine levels in bronchoalveolar fluid lavage from patients with interstitial lung diseases. Scand. J. Clin. Lab. Invest. 2003; 63: 27-36. (Pubitemid 36461147)
28. Zissel G, Homolka J, Schlaak J, et al,. Anti-inflammatory cytokine release by alveolar macrophages in pulmonary sarcoidosis. Am. J. Respir. Crit. Care Med. 1996; 154: 713-19. (Pubitemid 26327296)
29. Limper AH, Colby TV, Sanders MS, et al,. Immunohistochemical localization of transforming growth factor-beta 1 in the nonnecrotizing granulomas of pulmonary sarcoidosis. Am. J. Respir. Crit. Care Med. 1994; 149: 197-204. (Pubitemid 24066120)
30. Salez F, Gosset P, Copin MC, et al,. Transforming growth factor-beta1 in sarcoidosis. Eur. Respir. J. 1998; 12: 913-19.